Research and Markets: Key Findings From Treatment Algorithms: Psoriatic Arthritis

DUBLIN--(BUSINESS WIRE)-- Research and Markets ( has announced the addition of Decision Resources, Inc's new report "Key Findings from Treatment Algorithms: Psoriatic Arthritis" to their offering.

Psoriatic arthritis (PsA) is a chronic inflammatory disorder characterized by multiple, heterogeneous manifestations, including peripheral arthritis, axial disease, and psoriasis. Tumor necrosis factor-alpha (TNF-a) inhibitors are a mainstay of PsA treatment; since the approval of the first TNF-a inhibitor, Amgen/Pfizer's Enbrel (etanercept), in 2002 and through the subsequent launches of Janssen Biotech's Remicade (infliximab) and Abbott's Humira (adalimumab), the TNF-alpha inhibitors have made steady inroads into the PsA treatment algorithm.

These agents have secured competitive advantages over one another based on various attributes—efficacy on skin manifestations, physician perceptions regarding safety, mode of administration, and dosing frequency.

The 2009 launch of Janssen Biotech's Simponi (golimumab), which offers the most convenient choice among all the approved TNF-a inhibitors (a once-monthly subcutaneous delivery), could pose a competitive challenge to the established agents. Using patient-level claims data, this report determines the share of each currently marketed drug by line of therapy, evaluates therapy flow, and analyzes why key drugs are chosen over others.

Key Topics Covered:

1. Background

a) Publication Update

b) Report Contents and Features

c) Current Practice Guidelines

d) Key U.S. Market Events Influencing Treatment Selection

2. Key Findings for Newly Diagnosed Patients

a) Executive Summary

b) Graphical Views

3. Key Findings for Recently Treated Patients

a) Executive Summary

b) Graphical Views

4. Key Findings by Product

a) Enbrel

b) Humira

c) Remicade

d) Simponi

5. Appendix: Methodology

For more information visit

Source: Decision Resources, Inc

Research and Markets
Laura Wood, Senior Manager
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare and Medical Devices, Pharmaceuticals

Source: Research and Markets